Lewis S, Glen J, Dawoud D, et al. - For patients admitted for elective total knee replacement surgery, all available prophylaxis strategies to reduce the incidence of venous thromboembolism were assessed with respect to their relative efficacy and safety, in this systematic review and Bayesian network meta-analyses of randomized controlled trials. The included studies were identified from the Cochrane Library (CENTRAL), Embase, and Medline searched till June 19, 2017. Deep vein thrombosis (symptomatic and asymptomatic), pulmonary embolism, and major bleeding were assessed as outcomes. The network meta-analyses included 25 randomised controlled trials. Findings revealed a greater efficacy of single prophylaxis strategies vs combination strategies as a prophylactic against deep vein thrombosis development in the elective total knee replacement population. For deep vein thrombosis prevention, rivaroxaban ranked first. In the pulmonary embolism network, the first rank was conquered by low molecular weight heparin (LMWH; standard prophylactic dose, 28–35 days). In the major bleeding network, LMWH (low prophylactic dose, 10–14 days) ranked first. As for pulmonary embolism and major bleeding, the results were highly uncertain.